RINKEL MOLD MIX C is a Percutaneous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Allergy Laboratories, Inc.. The primary component is Absidia Capillata; Acrothecium Robustum; Microsporum Audouinii; Microsporum Canis; Apiospora Montagnei; Phycomyces Blakesleeanus; Sporotrichum Pruinosum; Stachybotrys Chartarum; Syncephalastrum Racemosum; Tetracoccosporium Paxianum; Verticillium Albo-atrum; Thermomyces Lanuginosus; Trichosporon Cutaneum.
| Product ID | 54575-230_dbe7bebd-e445-4e59-8302-e706b795fbde |
| NDC | 54575-230 |
| Product Type | Human Prescription Drug |
| Proprietary Name | RINKEL MOLD MIX C |
| Generic Name | Absidia Capillata And Acrothecium Robustum And Microsporum Audouinii And Microsporum Canis And Apiospora Montagnei And Phycomyces Blakesleeanus And Sporotrichum Pruinosum And Stachybotrys Chartarum An |
| Dosage Form | Injection, Solution |
| Route of Administration | PERCUTANEOUS; SUBCUTANEOUS |
| Marketing Start Date | 1967-12-07 |
| Marketing Category | BLA / BLA |
| Application Number | BLA101376 |
| Labeler Name | Allergy Laboratories, Inc. |
| Substance Name | ABSIDIA CAPILLATA; ACROTHECIUM ROBUSTUM; MICROSPORUM AUDOUINII; MICROSPORUM CANIS; APIOSPORA MONTAGNEI; PHYCOMYCES BLAKESLEEANUS; SPOROTRICHUM PRUINOSUM; STACHYBOTRYS CHARTARUM; SYNCEPHALASTRUM RACEMOSUM; TETRACOCCOSPORIUM PAXIANUM; VERTICILLIUM ALBO-ATRUM; THERMOMYCES LANUGINOSUS; TRICHOSPORON CUTANEUM |
| Active Ingredient Strength | 0 g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL |
| Pharm Classes | Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2018-12-31 |
| Marketing Start Date | 1967-12-07 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA101376 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1967-12-07 |
| Inactivation Date | 2020-01-31 |
| Marketing Category | BLA |
| Application Number | BLA101376 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1967-12-07 |
| Inactivation Date | 2020-01-31 |
| Marketing Category | BLA |
| Application Number | BLA101376 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1967-12-07 |
| Inactivation Date | 2020-01-31 |
| Marketing Category | BLA |
| Application Number | BLA101376 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1967-12-07 |
| Inactivation Date | 2020-01-31 |
| Ingredient | Strength |
|---|---|
| ABSIDIA CAPILLATA | .076 g/20mL |